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SPECTROSCOPIC DETECTION OF PATHOLOGICAL  
 
SEVERITY IN ALZHEIMER’S DISEASE  
 
JAMES PHILIP HERPY 
ABSTRACT 
 Alzheimer’s disease (AD) has emerged as one of the most widespread and 
devastating forms of dementia. Over the past few decades, AD has consistently increased 
in prevalence worldwide due to the rising proportion of elderly individuals and lack of 
effective screening and treatment modalities. To date, few economically viable and 
widely applicable tools exist to make definitive, early diagnoses of the disease. 
Therefore, there is a clear need for interventions that facilitate accurate diagnoses, 
monitoring, and therapeutic treatment of AD.  
 In the course of AD, cognitive impairment is preceded by physiological changes 
to the central nervous system (CNS). This includes neuronal atrophy, synaptic 
dysfunction, and the abnormal post-translational modification of the proteins tau and 
beta-amyloid (Aβ), which contributes to the deposition of intracellular neurofibrillary 
tangles (NFTs) and extracellular neuritic plaques (NPs). The pathological cellular 
changes in AD occur long before the clinical course of the disease, and biomarkers for 
these changes can be detected prior to measurable cognitive decline. Because the 
biochemical changes associated with AD are irreversible, effective tools for diagnosis 
must detect the presence and severity of molecular pathology during the preliminary 
stages of the disease’s insidious onset.  
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 Biomarkers of AD can be detected by neuroimaging technologies, including 
magnetic resonance imaging (MRI), positron emission tomography (PET), and blood or 
cerebrospinal fluid (CSF) analyses. However, these methods are not currently suited to 
diagnose and monitor the unique pathogenesis of AD prior to cognitive decline. An ideal 
instrument for widespread AD screening, diagnosis, and monitoring must be noninvasive, 
inexpensive, portable, and accommodating to the cognitive sensitivities of patients on a 
spectrum from mild cognitive impairment (MCI) to full-blown dementia. Recently, 
several spectroscopic methods of assessing AD pathology have met these criteria and 
may be better suited for widespread clinical application. 
 The objective of this thesis is to evaluate the use of near-infrared optical 
spectroscopy (NIRS) to detect pathological severity in human AD. Near-infrared (NIR) 
light is poorly absorbed by biological tissue, and can safely penetrate bone, skin, 
vasculature, and neuronal tissue. NIRS has traditionally been used in biomedical contexts 
to evaluate cerebral oxygenation changes, however the dense protein aggregates NFTs 
and NPs in AD tissue have recently been shown to characteristically affect several optical 
parameters of a NIR signal, including fluorescence and particle path (scattering). To date, 
applications of NIRS have been used to differentiate AD brains from non-AD controls in 
vitro, and further identify MCI patients in vivo, suggesting the NIR signal can identify 
molecular changes in AD. Severe AD cases are characterized by increased involvement 
of NFTs and NPs in the cerebral cortex, which would be expected to further affect the 
extent of NIR scatter. The current study aims to quantify AD-related pathology for 
investigation into whether the extent of optical scattering is correlated with the severity of 
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amyloid plaque load and NFT density in the temporal cortex. Quantification of these 
lesions was accomplished using immunohistochemistry (IHC) and stereological analyses. 
Preliminary results show that the severity of AD pathology detected via IHC can be 
correlated with measured parameters of an in vitro near-infrared signal. Future studies 
aim to further characterize the relationship between scattering intensity and pathological 
severity, as well as evaluate the in vivo potential of this technology in predicting the 
clinical outcome and cognitive status of individuals in different stages of AD. 
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INTRODUCTION 
 
 Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
characterized by impairment of functional, behavioral, and cognitive processes. 
Symptoms of AD generally include memory loss, language impairment, mood swings, 
and general delusions (McKhann, et al., 2011). The neuropathological features of AD 
were first described by German physician and researcher Alois Alzheimer, who noted the 
presence of aggregated cellular materials in the cerebral cortex during a postmortem 
assessment of an elderly woman with dementia (Alzheimer, 1987). Alzheimer’s 
neuropathological analysis revealed the abnormal cortical lesions that are now known to 
be two hallmark histopathological features of AD: dense, intracellular protein aggregates 
known as neurofibrillary tangles (NFTs) and extracellular neuritic plaques (NPs). The 
plaques associated with AD contain dystrophic neurites and an abnormally processed 
form of the protein amyloid, while the predominant component of NFTs is a hyper-
phosphorylated form of the microtubule-stabilizing protein tau (Perl, 2010).  
 Although the distinct cellular processes leading to AD are agreed to be 
progressive and irreversible, much of the specific pathophysiological mechanisms 
surrounding the deposition of NPs and NFTs remain controversial. The events initiating 
the formation of both pathological lesions tend to occur early in the disease process, 
during the newly-defined “preclinical” phase of AD, which is not associated with 
measurable cognitive impairment (Zhao, et al., 2016; Sperling, et al., 2013). A formal 
prognosis is often declared at the more advanced stages of disease, at which point 
patients experience a relentless and terminal progression of cognitive decline 
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(Villemagne, et al., 2013). As such, much of the current research in the field of AD 
staging and diagnosis is focused on the discovery of clinically relevant biomarkers that 
appear during the earliest stages of the disease. 
 
AD Epidemiology 
Incidence of AD 
 Alongside the aging world population, successful AD intervention is poised to 
become a formidable challenge to global public health. To date, AD is the most common 
clinically-relevant presentation of dementia, representing 75% of all cases, and the 
number of persons living with the disease is projected to increase from 26.6 million in 
2006 to over 100 million worldwide by the year 2050 (Brookmeyer, et al., 2007; Qiu, et 
al., 2009). Aging is the most significant risk factor for the development of AD, and in the 
United States alone, 32 percent of individuals aged 85 and older have AD, while only 19 
percent of Americans with AD are younger than age 75 (Hebert, et al., 2013). However, 
AD is fundamentally a multifactorial condition, and the link between old age and AD 
may be reinforced by a lifetime of exposure to environmental risk factors and/or the 
potential inheritance of genetic susceptibility loci (Baumgart, et al., 2015; Fratiglioni, et 
al., 2008; Huang, et al., 2004; Lambert, et al., 2013). 
 With the current treatment and diagnostic modalities in place, and barring any 
unprecedented advancements, AD and its family of related neurocognitive disorders will 
continue to contribute significantly to the collective cost of health care in the United 
States and globally. A worldwide prevalence of over 44 million individuals with 
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dementia represents an estimated financial burden of over 600 billion USD, leading to 
massive economic consequences on behalf of both the individuals and communities 
affected (Prince, et al., 2014; Wimo, et al., 2006; Qiu, et al., 2009). The growing 
incidence of AD worldwide demonstrates a profound financial burden and reveals the 
need for technical advancements that provide physicians and researchers with 
economically viable strategies for intervention.  
AD Clinical Course 
 The course of AD includes the following stages: preclinical AD, MCI due to AD, 
and probable or possible AD with varying severities (mild, moderate, and severe) (De-
Paula, et al., 2012). Despite these classifications, there is no routine clinical course of 
AD, as the onset and severity of symptoms is often inconsistent across individuals 
(McKhann, et al., 2011). Currently, initial clinical diagnoses are performed using a 
battery of neurocognitive tests that are sometimes followed by biomarker screening or 
neuroimaging analysis. However, a definite AD diagnosis, and indication of severity, can 
currently only be given after postmortem histopathological analysis of the brain, at which 
time a pathologist confirms the presence and distribution of NFTs and NPs (Perl, 2010; 
Braak & Braak, 1991).  
 The clinical diagnosis generally ascribed is that of probable AD, and it is not 
typically made until several years after the asymptomatic, preclinical phase of the disease 
(Sperling, et al., 2011). Individuals with this diagnosis must first meet the criteria for 
major neurocognitive disorder (MNCD, previously known as dementia), before they are 
also evaluated for symptomology that is characteristic of AD. 
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 The DSM-V recommended criteria for MNCD requires that individuals have 
deteriorated from an earlier degree of ability in areas such as memory, language, complex 
attention, perceptual-motor ability, and social cognition (American Psychiatric 
Association, 2013). The deficit may come in the form of a worsened ability to retain new 
information (forgetfulness), impaired reasoning (poor planning and decision-making), 
impaired language function (aphasia or apraxia), and behavioral changes (mood 
instability) (McKhann, et al., 2011). Noteworthy behavioral and cognitive symptoms 
must also compromise one’s independence in completing vital tasks, such as managing 
finances or health care (American Psychiatric Association, 2013). 
 In cases of suspected AD, MNCD can be further categorized as probable AD (or 
possible AD in cases of lower diagnostic certainty) (McKhann, et al., 2011). In addition 
to the criteria for MNCD, these classifications require a gradual, progressive onset, an 
extended history of decline, an amnestic or nonamnestic presentation (Table 1); and the 
lack of evidence implicating alternative neurocognitive conditions or cerebrovascular 
disease/stroke. (McKhann, et al., 2011). To better improve diagnostic certainty for those 
who meet the core criteria for AD, imaging studies (MRI or PET) or biomarker screening 
at the time of diagnosis may be used in conjunction with the cognitive and behavioral 
analyses, however these approaches currently lack accepted standards required to make 
either an independent diagnostic alternative (McKhann, et al., 2011; Weiner, et al., 2015). 
 The more nuanced diagnosis of MCI rests upon the clinician’s subjective 
assessment of whether or not the symptoms have compromised functioning in normal 
daily work or activities. These individuals typically experience minor changes to memory 
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and cognition that are unlikely to impact routine tasks, personality, and social 
relationships (Schneider, et al., 2009; Petersen, et al., 1999). There are divergent clinical 
outcomes for those with MCI, including stable MCI, or further cognitive deterioration 
that culminates in dementia/AD (Figure 1). MCI that will progress to probable AD is 
clinically indistinguishable from the other 80% to 90% of cases unrelated to AD, in 
which cognition may remain stable throughout future aging (Sperling, et al., 2013; Farias, 
et al., 2009). Identifying individuals specifically with AD-associated MCI has been an 
area of continued research, and is centered around the use of early diagnostic biomarkers 
and advanced molecular imaging techniques (Albert, et al., 2011; Schneider, et al., 2009; 
Jack Jr, et al., 2008). 
 
Neuropathological Changes in AD 
Gross Morphological Changes in AD 
 The brain of a patient suspected to have AD does not exhibit any gross 
morphological alterations that can be used to confidently render a diagnosis (Perl, 2010). 
AD brains often display nonspecific changes that result from normal aging and are 
observed in non-demented, elderly individuals (Jellinger, 1990; Perl, 2010). However, 
some abnormalities may be generally suggestive of AD, such as neuronal atrophy in the 
frontotemporal association cortex, cortical thinning, or dilation of the lateral ventricles 
(ex vacuo hydrocephalus) (Perl, 2010; Dickerson, et al., 2009; Dickerson, et al., 2011). 
Although these observations have been correlated with an AD diagnosis, they are not 
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viable diagnostic criteria because they also appear in different types of progressive 
dementias (Jellinger, 1990; Terry, 1986).  
Cellular/Biochemical Changes in AD 
 Symptoms of AD do not manifest until several years after the onset of underlying 
pathophysiological processes (Sperling, et al., 2011; Sperling, et al., 2013). Current 
research suggests that during the asymptomatic preclinical stage, irreparable damage to 
the CNS has already begun to take place, and abnormal amounts of Aβ plaques/NFTs 
have begun to accumulate (Stargardt, et al., 2015). Later, secondary changes to the 
neuronal landscape parallel the course of cognitive decline. These changes include 
synaptic dysfunction and neuronal atrophy, which are detectible as early as the MCI stage 
of AD, and possibly during the preclinical stage (Villemagne, et al., 2013; DeKosky ST, 
1990; Ingelsson, et al., 2004). Much of the morphological changes associated with 
cognitive impairment in AD are irreversible, which highlights the importance of 
determining diagnostic biomarkers and monitoring techniques that indicate the causal 
cellular processes have occurred. 
 A definitive AD diagnosis can only be made with certainty after histological 
examination of the brain, which involves a semi-quantitative analysis/staging of NPs and 
NFTs in the brain (Khachaturian, 1985; Mirra, et al., 1991; Mirra, et al., 1997; Braak & 
Braak, 1991; Braak, et al., 2006). Although NPs and NFTs are the histopathological 
features most closely associated with AD, the disease is also associated with the 
following cellular observations: tau-positive dystrophic neurites, diffuse neuropil threads, 
activated microglia, astrogliosis, atrophy of neuronal dendrites, and amyloid deposits 
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near cerebral vasculature (congophilic amyloid angiopathy, CAA) (Mandelkow & 
Mandelkow, 1988; Itagaki, et al., 1989; Ringman, et al., 2014).  
Neuropathology of MCI with AD Pathology 
 Studies involving patients with MCI have demonstrated that AD symptoms and 
pathology exists on a continuum, with MCI representing an intermediate stage of both 
cognitive impairment and NP/NFT involvement (Petersen, et al., 1999). The majority of 
clinical MCI cases represent a transition point from healthy aging to AD, as moderate 
AD-related pathology has been observed in MCI that will progress to AD dementia. 
Pathology observed during this stage includes amyloid deposition, neuronal loss in the 
entorhinal cortex, and NFT deposition in MCI analogous to Braak Stage III (Schneider, et 
al., 2009). This qualifies these patients as “at risk” for future development of AD and 
progressive cognitive decline. As such, neuroimaging methods that detect abnormal 
quantities of NPs/NFTs during the MCI stage would help identify these individuals for 
which AD progression is a potential concern.  
 
Amyloid Pathology in AD 
Aβ Plaque Morphology & Topography 
 Amyloid plaques appear in the form of “dense-core amyloid plaques,” also known 
as senile plaques (SPs), or neuritic plaques (NPs) when associated with dystrophic 
neurites (Perl, 2010). NPs are diagnostic of AD, and are stereotypically spread 
throughout the neocortex, with late-stage pathology appearing in the 
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hippocampus/entorhinal cortex (Thal, et al., 2002). Interestingly, normal aging is also 
associated with asymptomatic amyloid deposition in the form “diffuse” amyloid plaques. 
These are thought to increase in quantity throughout aging and may or may not be 
observed in cognitively-intact elderly individuals during autopsy (Terry, 1986; 
Villemagne, et al., 2013). However, neither the effect of diffuse amyloidosis in normal 
aging nor its potential link to AD/MCI have not been clearly described. 
 The extent of amyloid deposition, or “plaque load”, is one criterion for 
determining the severity of AD during postmortem analysis. In Braak Staging, three 
stages with increasing severity (I, II and III) have been proposed. Stage I is ascribed 
when amyloid deposits are found predominantly in the basal regions of the temporal, 
occipital and frontal lobe. Stage II is associated with additional amyloid pathology in the 
hippocampus, and Stage III represents the deposition of amyloid plaques in all of the 
above areas and the cerebellum and/or regions of the subcortical nuclei (Braak & Braak, 
1991). Amyloid plaques associated with AD are distributed throughout layers I-VI of the 
neocortex, with the most predominant pathology often observed in layers II-V (Arnold, et 
al., 1991). The distribution and morphology of different plaque types are examined 
immunohistochemically using antibodies directed against specific isoforms of the Aβ 
protein (Figure 2), or hyper-phosphorylated tau, which is found within dystrophic 
neurites surrounding NPs (Figure 3) (Perez, et al., 2008). 
Biochemistry of Aβ Protein 
 The extracellular amyloid plaque deposition in AD is driven by the pathogenic 
processing of the amyloid precursor protein (APP) into the protein beta-amyloid (Aβ). 
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The APP polypeptide is expressed from the APP gene located on chromosome 21q21.3, 
and is thought to normally be involved in several diverse physiological processes, 
including neuronal repair mechanisms, neuronal growth/survival, and stem cell maturity 
(Dawkins & Small, 2014). Even in the absence of disease, APP undergoes extensive post-
translational processing, including the addition of phosphates, sulfates and carbohydrates, 
as well as cleavage by secretase enzymes (Selkoe, 2001).  
 The pathogenic form of amyloid is the 37-43 amino acid peptide Aβ (Haas, C, et 
al., 2012). Proteolytic processing of APP into Aβ involves an initial N-terminal cleavage 
by the protease β-secretase (BACE1), generating a membrane-bound domain of Aβ, 
followed by γ-secretase activity, which releases the Aβ molecule (Figure 4) (Haas, C, et 
al., 2012; Vassar, et al., 2010). The insoluble Aβ monomers are misfolded in a 
conformation that facilitates aggregation into soluble oligomers that constitute dense 
amyloid plaques. Fibrillated Aβ oligomers are neurotoxic, and are suspected to play an 
extensive role in the pathology of AD (Hardy & Selkoe, 2002). As the concentration of 
Aβ increases, a theoretical threshold is reached in which Aβ oligomers initiate the 
misfolding and aggregation of additional Aβ in a chain-reaction known as secondary 
nucleated polymerization (Haas, C, et al., 2012; Cohen, et al., 2013; Vassar, et al., 2010). 
 Two specific forms of Aβ protein have been implicated in plaque formation and 
are thought to be closely linked to the pathogenesis of AD: a 40-amino acid isoform 
(Aβ40) with intermediate solubility, and the notable 42-amino acid isoform (Aβ42), 
which has poorer solubility and an increased tendency to aggregate extracellularly 
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(Serrano-Pozo, et al., 2011). Aβ42 is the predominant isoform found in NPs, while SPs in 
general contain both Aβ40 and Aβ42 (Lue, et al., 1999). Amyloid pathology has been 
detected via PET and biomarker screening prior to the onset of cognitive decline, 
suggesting that the shift towards neurotoxic processing of APP is an early event in the 
disease’s course, and may potentially be an area of diagnostic significance with more 
sensitive imaging technologies (Ingelsson, et al., 2004; Stargardt, et al., 2015; Vlassenko, 
et al., 2012; Villemagne & Chetelat, 2016). 
The Amyloid Cascade Hypothesis 
 Despite the presence of Aβ early in the course of AD, it is not yet clear how 
plaque deposition systematically leads to the symptoms of AD. One of the earliest 
hypotheses concerning the etiology of AD described Aβ, and the formation of NPs, as the 
causative factors leading to formation of NFTs, neuronal atrophy and subsequent 
cognitive impairment in AD (Hardy & Higgins, 1992). This became known as the 
Amyloid Cascade Hypothesis (ACH). The ACH has been an extremely influential, albeit 
controversial, topic in the past 25 years of Alzheimer’s research (Armstrong, 2014). 
 The key evidence leading to the proposition of the ACH was the early discovery 
of Aβ as the main constituent of amyloid plaques (Glenner & Wong, 1984). This was 
further supported by genetic research in Down’s Syndrome and familial Alzheimer’s 
disease (FAD), an autosomal-dominant variant of AD that has a distinct pathogenesis 
involving the mutation of presenilin genes (PSEN1 and PSEN2). Individuals with the 
genetic abnormalities associated with both FAD and Down’s Syndrome often exhibit 
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high levels of Aβ earlier than traditional, sporadic AD cases, and they are consequently at 
a significantly higher increase risk of developing AD (Ryan & Rossor, 2010).  
 While Aβ deposition has been documented during the earliest stages of AD, it is 
not certain if Aβ peptides alone are sufficient to initiate the neuronal atrophy and synaptic 
dysfunction that correlate well with cognitive decline in AD (Sperling, et al., 2011). 
However, the soluble Aβ42 oligomer is a potent neurotoxin, and has been shown 
experimentally to contribute to neurodegeneration and the deterioration of neuronal 
synapses (Lacor, et al., 2007). These findings have led to a modified-ACH, that describes 
the fibrillated Aβ42 oligomers, rather than monomeric Aβ, as a causative agent in the 
synaptic and neuronal dysfunction of AD, and that the specific mechanistic relationship 
between Aβ and extent of cognitive decline is still unclear (Reitz, 2012).  
 Recent studies have challenged several assumptions put forth in the ACH. For 
example, critics cite that a clear correlation between Aβ plaque load and clinical 
cognitive impairment has not yet been demonstrated, and that amyloid deposition may 
actually decrease late in the disease’s course due to microglial uptake of Aβ (Serrano-
Pozo, et al., 2011). Furthermore, findings suggest that the deposition of Aβ plaques is not 
a prerequisite event for NFT formation, as implied by the ACH. Instead, it is likely that 
tau and amyloid pathology are closely related but independent events, with separate 
physiological processes that likely share a related upstream cause (Small & Duff, 2008). 
 Despite its shortcomings, the ACH remains a prominent theory and has prompted 
a related body of therapeutic research focused solely on the early elimination and/or 
prevention of Aβ. This includes secretase-inhibitors and Aβ-targeting monoclonal 
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antibodies (Karran, et al., 2011). Consequently, this effort has consumed significant 
financial and scientific resources and prompted more questions regarding the legitimacy 
of the ACH. Very few of the proposed Aβ-centric therapeutics have affected the course 
of NP deposition, and none of the experimental compounds limiting or eliminating Aβ 
have succeeded in Phase III clinical trials (Lista, et al., 2014). 
 
Tau Pathology in AD 
AD as a Tauopathy 
 The intraneuronal inclusions described by Alois Alzheimer in his preliminary 
autopsy report are now known to be the dense protein aggregates called neurofibrillary 
tangles (NFTs). The biochemical properties of NFTs have been of great interest to 
researchers, as this type of lesion appears in several distinct human cognitive disorders, 
including argyrophilic grain disease (AGD), corticobasal degeneration (CBD), Pick’s 
disease (PiD), and Lewy body diseases, among others (Table 2) (Dickson, 2010). These 
neurocognitive disorders, in which NFTs are a central pathological feature, are 
collectively termed “tauopathies” after the primary structural component of the lesions: 
the protein tau (Perl, 2010). 
 Tau is a major microtubule-associated protein (MAP) that is expressed in neurons 
throughout the CNS. The physiological role of tau is to stabilize microtubules in the 
axonal compartment, predominantly by facilitating the assembly and polymerization of 
the monomer tubulin (Cleveland, et al., 1977). Normal tau activity is regulated by 
phosphorylation via protein kinases (glycogen synthase kinase 3 and p70-S6 kinase) and 
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phosphatases (protein phosphatase 2A). In AD, an imbalanced expression of these tau-
regulatory enzymes leads to hyper-phosphorylation (Pei, et al., 2008). Hyper-
phosphorylated tau has a decreased binding affinity for tubulin, causing it to dissociate 
from microtubules, become misfolded, and aggregate within the neuron in the form of 
NFTs or neuropil threads (Serrano-Pozo, et al., 2011). Six distinct isoforms of tau have 
been shown to be incorporated into NFTs in AD, despite their capacity to become 
phosphorylated at several different amino acid residues (Lee, et al., 1991; Goedert, et al., 
1992).  
NFT Morphology & Topography 
 Hyper-phosphorylated tau is prone to misfolding and aggregation into insoluble 
fibers known as “paired-helical filaments” (PHF-tau), which have been studied 
extensively following the discovery that PHF-tau is a predominant feature of NFTs 
(Wisniewski, et al., 1976). PHF-tau is now considered a hallmark feature of AD 
pathology, as it is additionally found in neuropil threads and the dystrophic neurites 
surrounding NPs (Goedert, et al., 1998). The transformation of PHF-tau into NFTs, 
which are toxic to neurons, is now thought to accompany Aβ production as a central 
event in the pathophysiology of AD. The process of neuronal degeneration initiated by 
NFTs in AD is known as neurofibrillary degeneration, although PHF-tau-positive cells 
have been observed also undergoing apoptosis (Pei, et al., 2008). 
 The spatial distribution of NFTs throughout the course of AD is generally 
consistent and, like NPs, is associated with a unique post-mortem staging scheme (Braak, 
et al., 2006; Braak & Braak, 1991). Interestingly, the spatial location of early NFT 
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deposition differs from that of amyloid, as NFTs first appear in the entorhinal cortex and 
hippocampus, later spreading to the associative areas of the neocortex and possibly 
visual/motor/sensory areas in the most severe cases (Serrano-Pozo, et al., 2011; Braak, et 
al., 2006). The presence and distribution of NFTs can also be assessed using applications 
of immunohistochemistry with antibodies that target PHF-tau (Figure 5).  
Tau Hypotheses 
 Recent works establishing the early appearance of PHF-tau and its relationship to 
cognitive impairment have led researchers to consider the role of tau misfolding as a 
prominent component of AD pathophysiology. In support of this hypothesis, NFT density 
is more strongly correlated with the extent and chronology of dementia compared to the 
quantity of NPs (Ingelsson, et al., 2004). Also, tau pathology has been observed prior to 
amyloid deposition in some instances, and may actually foreshadow the onset of AD as 
early as 20+ years prior to symptoms (Braak & Del Tredici, 2011). Following these 
studies, modern therapeutic intervention has begun to involve amyloid- and tau-targeting 
combination therapies. Several potential drugs that prohibit the pathological formation of 
PHF-tau have been developed that target the tau-regulatory kinases and phosphatases 
mentioned above (Pei, et al., 2008). 
 Further evidence of tau’s pathological role in AD symptomology lies in the 
characteristic regional deposition of NFT throughout the course of the disease. Studies 
have shown that neurofibrillary degeneration in specific brain regions can be used to 
predict the onset/severity of related AD symptoms. For instance, the impairment of 
episodic memory generally occurs early in the onset of AD symptoms, and correlates 
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with the earliest neurofibrillary degeneration that divorces the hippocampus from the 
associative neocortex. This may also explain why late in the disease’s course, motor 
functions and vision are largely unimpaired and sparse tau-pathology is found in the 
motor/visual areas of the neocortex (Braak, et al., 2006; Serrano-Pozo, et al., 2011). 
Nonetheless, this relationship between regional tau-pathology and the onset or severity of 
associated symptoms is speculative. Similar to amyloidosis, it is not yet clear if NFT 
formation and neurofibrillary degeneration are obligatory processes in the symptomology 
of AD. 
 
AD-Based Biomarkers & Neuroimaging 
Overview of Classic AD Imaging Modalities 
 Biomarker analyses may have the greatest potential for refining AD diagnostic 
schema, predicting patient outcomes in individuals with MCI, and evaluating the efficacy 
of therapeutics. Compared to histology, which is limited to postmortem examination of 
the brain, neuroimaging can be implemented throughout the course of AD and track 
changes in brain morphology. Pathology associated with AD can be tracked through: 
morphometric changes (using MRI), metabolism abnormalities (using fMRI), and 
biochemical changes (using longitudinal biomarker screening in serum or CSF) 
(Schmand, et al., 2010). Optical techniques, including the use of near-infrared 
spectroscopy (NIRS) and functional near-infrared spectroscopy (fNIRS), have also been 
recently explored as potential tools for gathering metabolic, anatomical and biochemical 
data (Cui, et al., 2011; Hintersteiner, et al., 2005). Use of these methods to observe 
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quantitative changes in specific biomarkers will ideally clarify the timeline of cellular 
changes in AD and the relationship between tau pathology, amyloidosis, and 
neuronal/synaptic malfunction. The neuroimaging modalities described below are 
currently applied in the study of AD, and may better our understanding of the link 
between pathophysiological changes and the manifestation of symptomology in AD. This 
has the potential to inform current and future therapeutic research, and allow 
diagnostic/treatment modalities to be implemented more effectively.  
CSF- & Blood-based Biomarkers 
 Several blood- and CSF-based protein biomarkers have been evaluated for 
diagnostic utility in AD. Peptides suggestive of amyloid buildup circulate in both blood 
and CSF, and have been analyzed using blood/CSF analyses as well as applications of 
positron emission technology (PET) (Klunk, et al., 2004; Palmqvist, 2016). One such 
protein biomarker found in CSF is Aβ42, which is suggestive of AD when concentrations 
are decreased (Villemagne & Chetelat, 2016). This is thought to result after 
suprathreshold levels of Aβ have been reached that facilitate Aβ fibril aggregation, which 
may be inhibited from entering the CSF (Spies, et al., 2012). Changes in CSF 
concentration of Aβ42 are detectable early in the disease’s course, leading it to emerge as 
a widely studied in vivo biochemical marker of preclinical AD. In general, CSF-based 
biomarkers are thought to be more accurate indicators of the cerebral environment than 
blood, as the CSF more closely reflects the chemistry of the brain. However, the 
acquisition of CSF is relatively more invasive than the acquisition of blood, as CSF is 
often collected via lumbar puncture.  
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 Early blood-based biomarkers of AD have been also actively researched, as the 
discovery of a single blood-test for AD would presumably meet the criteria for a widely 
applicable diagnostic tool (cheap, non-invasive, easily administered). However, protein 
compounds in blood that carry diagnostic significance for AD have so far remained 
elusive. It is generally more difficult to measure blood-levels of CNS-derived proteins as 
they are likely to be highly diluted in systemic circulation. Nonetheless, several potential 
compounds have been reported, including Aβ40, granulocyte-colony stimulating factor 
(GCSF), stromal cell-derived factor 1 (SDF-1), and brain-derived neurotrophic factor 
(BDNF), but they are not yet suitable diagnostic measures due to their lack of specificity 
and accepted standards (Laske, et al., 2011).  
MRI Neuroimaging in AD 
 Although indirect markers in blood and CSF have begun to play a role in 
diagnosis and monitoring of AD, a more compelling marker of AD pathology would be 
targeted directly to the brain itself. As such, neuroimaging of the brain to examine 
architectural and chemical changes has greatly improved our understanding of AD 
pathology, yet several shortcomings in the field necessitate further technological 
advancements before it can be used independently in diagnosing AD. 
 To date, computed tomography (CT) and MRI have been used during the initial 
clinical diagnosis of AD to eliminate alternative causes of dementia, while further 
applications of MRI in morphometric studies have shown that the brain undergoes 
progressive atrophy throughout the course of AD (Johnson, et al., 2012). Volumetric 
decreases in the brain are thought to be associated with neuronal and dendritic/synaptic 
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losses, and MRI has been an instrumental tool in showing that this process follows the 
chronological spread of neurofibrillary tangles throughout the course of AD, implicating 
neurofibrillary degeneration (Scahill, et al., 2002). Furthermore, the rate and severity of 
neuronal atrophy have been shown to be closely correlated with clinical measures of 
cognitive decline (Cardenas, et al., 2011). However, MRI is limited in the sense that it 
cannot clearly differentiate between types of molecular inclusions, such as tau or amyloid 
pathology. Also, administering MRI is logistically demanding and cumbersome, which 
may be prohibitive when assessing patients with severe end-stage dementia or 
claustrophobia (Johnson, et al., 2012). 
 As of late, functional MRI (fMRI) has begun to play a central role in the study of 
neuronal and synaptic integrity in patients with AD and dementia. Here, the application 
of fMRI allows researchers to evaluate changes in blood flow, blood volume, and 
hemoglobin oxygenation at localized areas of the brain during cognitive tasks. These 
parameters are thought to mirror the integrity of synaptic activity (Logothetis, et al., 
2011). Unfortunately, the independent use of fMRI has not yet proven to be of diagnostic 
significance in AD. Recent studies using fMRI in patients with MCI, or a genetic risk for 
AD, have reported both decreased and increased temporal lobe activation during 
cognitive tasks, which suggests there may be a confounding compensatory effect early in 
the course of the disease (Johnson, et al., 2012). These findings come from a small 
number of groups with specific research parameters. As such, a fair assessment of the 
potential for fMRI in diagnosing AD requires more diverse study involving different 
populations of patients at varying stages of cognitive impairment. 
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PET Applications with Glucose, Amyloid, Tau Tracers 
 Positron emission technology (PET) has also been used extensively to study AD-
related changes in vivo. This system requires the administration of a specifically designed 
radiolabeled ligand that can be of diverse structure and function to assess a variety of 
different parameters. In AD, PET has been used to measure metabolic activity in 
neuronal synapses by administering the glucose surrogate [18F]-fluorodeoxyglucose 
(FDG), which is metabolized in the brain (Johnson, et al., 2012). These studies suggest 
that metabolic discrepancies exist in brain regions throughout the course of MCI, and can 
be used to differentiate these cases from AD-associated cognitive impairment (Mosconi, 
et al., 2008; Mosconi, 2005). 
 The PET ligand [11C]-Pittsburgh Compound B (PiB) was designed to cross the 
blood brain barrier and bind to cerebral amyloid, and has been used to validate clinical 
AD diagnoses and track changes in plaque load (Risacher & Saykin, 2013). Measuring 
amyloid with PiB in MCI patients has also allowed clinicians to better predict cases that 
will likely progress to dementias; the MCI cases with the highest amyloid accumulation 
have been shown to have a greater likelihood of progressing to full-blown AD (Forsberg, 
et al., 2008). This relationship does not take into account the longitudinal changes in 
amyloid load of patients with MCI and AD, which is now believed to reach a threshold 
amount of amyloid early in the course of the disease, which decreases as individuals enter 
late stages cognitive decline (Jack Jr, et al., 2009). Further studies evaluating the 
relationship between early amyloid accumulation and AD risk in cognitively impaired 
individuals may improve diagnostic precision. 
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 The use of PET with tau-tracers is relatively new technology that has just begun 
to be applied to the study of dementias. These studies have been somewhat limited, as the 
tau protein is inherently more difficult to evaluate using PET due to its complexity 
(multiple isoforms are found in NFTs), location (intracellular), and abundance (much less 
concentrated than Aβ) (Dani, et al., 2016). Despite these difficulties, seven tau-sensitive 
tracers have been established and applied to the study of neurocognitive diseases. These 
molecules have not yet been used extensively in the field of AD, but warrant further 
design and research due to the involvement of tau in AD pathogenesis and the close 
correlation of NFTs with cognitive impairment (Dani, et al., 2016). 
 Overall, while the most advanced imaging technologies have improved our 
understanding of the complex pathophysiology of AD, it is not certain whether they can 
currently distinguish the early molecular changes leading to AD with certainty. Optimal 
improvements for blood, CSF, and neuroimaged biomarkers would involve the following: 
an ability to distinguish between AD and healthy controls in vivo, an ability to 
discriminate between the different etiologies of MCI, and an ability to discriminate 
between different types of dementias prior to the onset of irreversible symptoms. When 
used in combination with one another and cognitive testing, the current biomarkers 
appear to have the potential to validate clinical AD diagnoses. 
The Near-Infrared Window 
 Near-infrared spectroscopy (NIRS) is an emerging optical technique with several 
diverse biomedical applications. First described by Jobis (1977), the term “near-infrared 
window” illustrates the poor absorptive capacity of biological tissue in its interaction with 
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wavelengths near the infrared spectrum (600-1300nm). This property allows photons to 
propagate beyond the functionally “translucent” tissue to a depth of several centimeters, 
facilitating the noninvasive study of physical and chemical properties in underlying 
structures (Jobsis-Vandervliet, 1999).  
 The classic biomedical application of NIRS is to measure cerebral oxygenation 
changes to assess neuronal activity during cognitive tasks and activities. In a similar 
capacity as fMRI, NIRS can detect changes in the absorptive spectra of oxyhemoglobin 
(O2Hb) and deoxyhemoglobin (dHb) in cerebral vasculature (Steinbrink, et al., 2006). 
However, NIRS is often preferred over fMRI because optical techniques are generally 
more tolerant of movement. This allows spectroscopy to be used in a wide range of 
clinical applications, such as the study of cerebral activity in motor tasks, audio and 
visual perception, language, executive function, as well as in psychiatric diseases such as 
schizophrenia, anxiety, substance abuse, developmental disorders and dementias (Ferreri, 
et al., 2014).  
NIRS in AD Research 
 NIRS has also been applied to the study of AD. Several in vivo studies of cerebral 
oxygenation using NIRS in AD patients have succeeded in validating findings from 
previous research using fMRI and PET (Cui, et al., 2011; Choo, et al., 1995). NIRS has 
also begun to show diagnostic potential in studies that evaluate cerebral oxygenation in 
MCI and AD phenotypes during cognitive tasks (Nho, et al., 2012). While these studies 
have merit, they are limited in the sense that they indirectly assay brain integrity via 
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oxygen consumption; a more meaningful application of NIRS in AD would involve the 
direct detection of the molecular features of AD pathology in the brain.  
 Outside of studying cerebral oxygenation, NIRS has been applied to AD research 
in several capacities. Recently, exogenous fluorescent probes have been synthesized that 
interact characteristically with a near-infrared signal. These probes can be directed 
towards amyloid plaques to evaluate amyloidosis in AD (Tong, et al., 2015). To date, six 
fluorescent imaging probes have been developed with high in vitro affinities for Aβ, 
however, in vivo applications are currently limited by insufficiencies in each probe’s 
specific pharmacokinetic properties, such as: poor in vivo stability, low serum albumin 
affinity to facilitate circulation, non-specific binding, and inadequate lipophilicity (Tong, 
et al., 2015). Current probes have yet to control for these parameters, and thus are not 
currently suitable for clinical application. 
 Therefore, a study design in the field of AD using NIR spectroscopy to directly 
assess brain pathology without exogenous fluorescent probes is desirable. Several 
research groups have reported that auto-fluorescent biomarkers can be used identify 
pathological features of tissue in cancer and myocardial ischemia, suggesting that near-
infrared fluorescence carries information relating to distinct molecular features of 
diseased tissue (Alfano, et al., 1984; Lam, S; Macaulay, C; Palcic, B, 1993; Horvath, et 
al., 1994). When applied to cases of AD, this suggests that an optical signal in the near-
infrared spectrum also may also interact characteristically with NPs and/or NFTs. (Thal, 
et al., 2002; Hanlon, et al., 1999). Tracking changes in this signal could subsequently 
yield information regarding the underlying pathology in the brain.  
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 In fact, near-infrared spectroscopy has been used to show that the absorptive, 
fluorescence, and scattering effects of AD-related lesions can be of potential diagnostic 
significance in autopsy tissue (Choo, et al., 1995; Pizzi, et al., 1995; Hanlon, et al., 1999; 
Hanlon, et al., 2008). These experiments show the interaction between NIR light and AD 
brain lesions can be characterized in a way that enables researchers and clinicians to also 
verify the presence of AD markers in vivo. This warrants further investigation into the 
specific effects of NPs and NFTs on properties of near-infrared spectra. Full 
characterization of fluorescence, absorption, reflection, and scattering associated with AD 
pathology and the surrounding tissue offers the potential for non-invasive, accurate 
clinical diagnoses and in vivo monitoring of AD pathology throughout the course of the 
disease.  
AD-lesions Fluoresce and Scatter NIR light characteristically 
 Recently, a spectroscopic device that directly assesses AD pathology has been 
developed, accompanied by an algorithm capable of detecting features of cerebral 
abnormalities in AD (Hanlon, et al., 1999). This involves analyzing the unique 
fluorescence spectra generated in brains with AD. The fluorescence detected due to 
presence of dense NPs and NFTs can be used to formulate a calibration set to further 
distinguish AD and non-AD tissue, suggesting this technology may have diagnostic 
utility. The spectral signals were evaluated using principal component analysis (PCA) as 
reported by Hanlon, et. al (1999), yielding an algorithm that, when applied to blinded 
specimens, successfully discerned between the diseased and control tissue.  
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 This technology has been applied to also identify molecular features of AD using 
the optical scattering of AD and non-AD temporal poles in vitro (Hanlon, et al., 2008). 
This study provided additional insight into the use of spectroscopy for diagnosing AD. 
First, it showed that the optical “scattering” of reflectance spectra was a more sensitive 
indicator of AD pathology itself than the absorbance, which is thought to be diminished 
by the signal’s strong interaction with light-sensitive hemoglobin chromophores (Hanlon, 
et al., 2008). Furthermore, the slope of the near-infrared lineshape derived from the 
transmission/reflectance spectra was shown to be diagnostic. This is suggestive of the 
specific role played by NFTs and NPs in NIRS, as these dense protein aggregates are 
much larger than the surrounding cellular structures, and as such would likely scatter 
light uniquely (Hanlon, et al., 2008; Perelman, et al., 1998).  
 The merits of NIRS are evident in these studies that showcase the technique’s 
capacity to noninvasively acquire information at the molecular/biochemical level using 
optical parameters, without exogenous markers. However, the specific influence of 
quantities of NFTs and/or NPs on properties of a reflected near-infrared signal have not 
yet been established. 
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SPECIFIC AIMS 
 
 The goal of this study is to investigate the use of optical scatter, as detected by 
near-infrared spectroscopy (NIRS), as a diagnostic predictor of Alzheimer’s disease 
histopathology in the temporal pole. This involves the use of in-vitro spectroscopic 
measurements of the temporal pole in AD human subjects, characterization of the 
resultant optical scattering, and quantification of the classical features of AD pathology in 
the tissue specimens. Morphological features of interest in this study include: total 
amyloid plaque load and density of NFTs in the cerebral cortex of the temporal pole. This 
thesis will report the stereological analyses of these lesions to be correlated with NIR 
scattering data in a future manuscript. 
 This study utilizes a previously described application of NIRS to yield optical 
scattering data, as well as immunohistochemistry and stereology to provide qualitative 
and quantitative analyses of pathological tau and amyloid accumulation in the temporal 
poles of confirmed AD cases. In prior studies using related systems (Hanlon, et al., 2008; 
Hanlon, et al., 1999), specimens labeled “severe AD” at autopsy displayed scattering 
values that were distinct from cases of “moderate AD” and “non-AD” pathology. This 
system has also been used in vitro to discriminate between “AD-” and “non-AD” age-
matched control brains, signifying a potential diagnostic/clinical application of this 
technology. To date, a study correlating NIR scattering intensity with the quantified 
severity of AD histopathology has not yet been conducted. 
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 Use of NIRS to identify and/or predict the severity of AD pathology during the 
preclinical or MCI stages of the disease will allow clinicians to identify at-risk 
individuals earlier in the course of AD, enabling more effective treatment and 
intervention. 
 
Specific Aim 1:  To quantify amyloid and tau pathology in the temporal pole of 
confirmed AD cases using immunohistochemistry and 
stereological analysis. 
 
Specific Aim 2:  To correlate characteristics of light scatter measured by in vitro 
NIRS with the severity of Alzheimer’s disease pathology in the 
human temporal pole. 
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MATERIALS AND METHODS 
Subjects 
 Five human temporal pole specimens were obtained courtesy of Dr. Eugene 
Hanlon and the Bedford VA Medical Center at Edith Nourse Rogers Memorial Veteran’s 
Hospital (Bedford, MA). Informed consent was given and approved by the Bedford VA 
Medical Center Institutional Review Board (IRB). A probable-AD diagnosis for each 
subject was determined based on longitudinal neurological and cognitive status 
assessments, and postmortem diagnosis was confirmed by histopathological analysis. 
Each specimen diagnosed as having AD met the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) criteria for a classification of “definite Alzheimer’s 
disease” (Mirra, et al., 1991). The current study consisted of 5 temporal poles from a total 
of 3 individuals. The specimens used in this study were dissected at the posterior end of 
temporal pole encompassing the inferior, occipital, and superior temporal sulci, to yield a 
tissue block that was several cubic centimeters in volume. 
 The temporal cortex was targeted for this study because it is a brain region 
affected early in the progression of AD, and is an optimal site for in vivo optical analysis 
because of its relatively thin layer of overlying bone and tissue (Hanlon, et al., 1999).  
Near-Infrared Spectroscopy 
 Tissue blocks were flash-frozen following dissection and thawed prior to 
spectroscopic measurements. NIR analysis took place at room temperature, prior to 
staining or fixation. Gross tissue reflectance measurements were acquired for each 
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specimen in laboratory conditions. The incident light signal was produced by a 
water-filtered xenon arc lamp associated with the “delivery” fiber optic at the 
center of six “detection” fibers. The incident signal was administered to the 
surface of the tissue from a distance of 10 mm at an angle of approximately 30° in 
order to prevent confounding detection of the regular (specular) reflection of the 
incident light. In addition, a mirror was positioned behind the tissue to divert the 
path of photons that had penetrated the whole tissue. The fiber bundle terminated 
at a detection spectrograph (Acton SpectraPro 150) coupled to a charge coupled 
device (CCD) (DU-434-FI, Andor Technology) cooled to approximately -60°C. 
Reflectance spectra for each in vitro sample were recorded from 650-1050nm.  
Derivation of Scattering/Absorption Coefficients 
 The absorption and scattering coefficients were based on recorded tissue 
reflectance and transmission values using a derivation of the two-flux model, as 
previously described in (Hanlon, et al., 2008). Observed reflectance and 
transmission values were analyzed using modeled parameters resulting from 
Monte-Carlo simulations for relevant biological tissue. The experimental 
scattering and absorption coefficients were determined to be the values that gave 
the best-fit when applied to the modeled reflectance/transmission spectra. The NIR 
scattering data referenced in this study is not included in the following text, and 
will be reported in a future manuscript. 
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Tissue Processing 
 Each tissue block was fixed in PLP (4% paraformaldehyde/lysine/periodate, pH 
7.4) for 149-224 days at 4°C. Following fixation, a cryoprotection procedure was 
administered that included a 24-hour incubation in 0.1M phosphate buffer (10% glycerol, 
2% DMSO, pH 7.4) at 4°C, followed by a 14-day incubation in 0.1M phosphate buffer 
(20% glycerol, 2% DMSO, pH 7.4) at 4°C. The tissue blocks were then frozen in 2-
methyl-butane at -65°C, and stored at -80°C until sectioning. 
 Frozen temporal pole blocks were sectioned with a sliding microtome along the 
coronal plane (Figure 6). Each tissue block was sectioned at 40µm. Sections were placed 
in one of sixteen vials containing 18-24 sections spaced 640µm apart. Each vial contained 
a solution of 15% glycerol in 0.1M phosphate buffer (pH 7.4) and was kept at -80°C 
following a 48-hour acclimation period at 4°C.  
Thionin Staining 
One in sixteen vials was stained for Nissl substance using thionin (pH 4.8) to 
evaluate cellular organization, observe qualitative features of the tissue such as gliosis, 
and to delineate rough anatomical regions of the temporal pole. Tissue sections were 
mounted on gel-subbed slides and allowed to dry for 48 hours. After drying, the sections 
were defatted in a 1:1 mixture of chloroform and ethanol for 2 hours, rehydrated in 
decreasing concentrations of ethanol for 30 seconds (100%, 100%, 95%, 75%, 50%, 0%), 
then stained with thionin (0.05% thionin, pH 4.8). Sections were washed in deionized 
water, then dehydrated using the above concentrations of ethanol in ascending order. 
Staining intensity was qualitatively evaluated during dehydration to ensure an optimal 
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contrast between Nissl substance and other characteristics of the tissue. The slides were 
cleared in xylene and coverslipped using Permount (Fisher Scientific). 
APP Immunohistochemistry 
 One vial from each subject containing one-sixteenth of a complete temporal pole 
was thawed to room temperature and processed together. All wash steps were performed 
two times (10 minutes each) with light agitation at room temperature in 2mL/section 
solution of tris-buffered saline (TBS, 0.05M, pH 7.55). 
 Free-floating tissue sections were initially rinsed in TBS to remove the 
cryoprotectant solution. Antigen retrieval was performed by incubating sections in a 
solution of 90% formic acid for 10 minutes. Following an additional wash with TBS, the 
sections were incubated in 3% hydrogen peroxide (H2O2) for 30 minutes to quench 
endogenous peroxidase activity. This was followed by a wash step and blocking in a 
solution of 10% normal goat serum (NGS) and 0.5% Triton X-100 in TBS. Sections were 
then placed in primary antibody solution (5% NGS, 0.5% Triton X-100 in TBS) 
containing the mouse monoclonal anti-amyloid precursor protein (APP) antibody 6E10 
(1:1000, Biolegend). Sections were incubated in primary antibody buffer for 24 hours 
while lightly agitated at room temperature. 
 The following day, the sections were washed in TBS and incubated with a 
biotinylated goat anti-mouse secondary antibody (1:1000, Vector Laboratories) in a 
secondary antibody buffer (5% NGS, 0.5% Triton X-100 in TBS). Sections were washed, 
then incubated with an avidin-biotinylated horseradish peroxidase enzyme complex 
(1:200, Vectastain Standard ABC kit, Vector Laboratories) for 90 minutes. After a final 
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was with TBS, sections were developed for 8 minutes in a solution of TBS with 3’,3-
diamino tetrahydrocholoride (DAB, 0.05%, Sigma) and hydrogen peroxide (0.005%). 
The stained sections were mounted on gelatin-coated slides and air dried for 48 hours. 
Each mounted section was dehydrated in a series of ethanol of the following 
concentrations: 0%, 50%, 70%, 95%, 100%. Sections were cleared with xylene and 
coverslipped using Permount (Fisher Scientific). Negative controls lacking the primary 
antibody were run in parallel with experimental sections, and no staining was observed in 
these samples. 
PHF-tau Immunohistochemistry 
 The following procedural differences were determined during optimization of the 
above IHC protocol and implemented while using the anti-PHF tau antibody AT8:  
A) Antigen retrieval prior to H2O2 incubation was performed by microwaving the 
sections in 10mM sodium citrate buffer (pH 6.05) at 550W (40°C) for 5 minutes, 
followed by a 60-minute incubation at room temperature in sodium citrate buffer.  
  B) The anti-PHF tau antibody AT8 (Thermo Fisher) was used at a concentration of 
1:250 in primary antibody diluent (5% NGS, 0.5% Triton X-100 in TBS) and was applied 
at 4°C for 48 hours. 
Antibody Characterization 
 6E10 (Biolegend) is a monoclonal antibody with an epitope in amino acids 3-8 of 
the beta amyloid protein. The antibody is reactive to amino acid residues 1-16, making it 
sensitive to several forms of the amyloid protein, including the pathologically spliced Aβ 
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and the unprocessed form, APP (Aho, et al., 2010). Only the aggregated extracellular 
species were included in the quantitative analysis using this antibody in order to prevent 
oversampling by including intracellular or non-pathological APP. 
 AT8 (Thermo Fisher) is a monoclonal antibody with an epitope at amino acids 
202 (serine) and 205 (threonine) of the protein tau. Reactivity at this site is maintained 
among all six tau isoforms when the residues are phosphorylated, as is the case in the 
PHF form of tau (Goedert, et al., 1995). Hyper-phosphorylation at these amino acids 
decreases the binding affinity for tau on associated microtubules, causing it to dissociate 
and form the paired helical structure that is known to aggregate within the neuron. PHF-
tau forms the characteristic neuropil threads and NFTs in the cerebral cortex of those with 
Alzheimer’s disease (Mandelkow, et al., 1993). 
The detailed technical specifications of the antibodies used in this study are summarized 
in Table 3. Concentrations of reagents are included in Appendix A. 
Stereological Analysis  
 For amyloid plaque analysis, a 10-16 section series encompassing every 16th 
section through the temporal pole was selected for quantification in each of the 5 cases. 
DAB-reactive amyloid deposits were identified using a 20x objective on a Nikon E600 
series microscope (Nikon, Melville, NY). The microscope was equipped with a motorized 
stage and encoder for z-axis measurements. The stereology software used was 
StereoInvestigator (MBF Biosciences) and the probe implemented was the Area Fraction 
Fractionator. The plaque load was estimated using the Cavalieri point counting scheme in 
which the reported “plaque load” represents the fraction of the temporal pole cortex 
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occupied by DAB-reactive amyloid plaques. A positive “Plaque” marker was applied 
when the deployed area-fraction probe overlapped with DAB-reactive plaques, 
distinguishable from background staining (Figure 7). 
 The tissue areas sampled were systematically selected by the StereoInvestigator 
software within a user-defined region of interest (ROI) that encompassed the whole gray 
matter (Figure 8). The ROI for each section was outlined using a 1x objective and 
excluded significant artefactual space or areas of damaged tissue. An area sampling 
fraction of 0.1127 was used to acquire an appropriate representative sample based on the 
the heterogeneity of plaque deposition. The parameters used with the area fraction 
fractionator probe are reported in Table 4. 
 The Optical Fractionator probe was used to count NFTs in a 6-9 section series 
encompassing every 32nd section of the temporal pole. This probe also uses systematic 
random sampling to yield unbiased estimates of NFT number by sampling regions within 
the ROI with equal probability. A pilot study was conducted to determine program 
specifications that meet the critical minimum values in each region of interest for the 
measured NFTs (grid size and dissector dimensions are reported in Table 5). Volume 
estimates of the region of interest were acquired using the reported sampling area and 
average tissue thickness measured at each unbiased sampling site. NFTs were identified 
within the dissector using a 40x objective. The counting object was immunoreactive 
perinuclear staining characteristic of NFTs, which was identified by distinguishing shape, 
neuronal processes, and stain intensity in comparison to background (Figure 9). A guard 
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limit was used to remove bias due to artefactual damage resulting from tissue sectioning 
above/below the dissector (Table 5).  
Technical Considerations 
 Procedural inconsistencies in fixation time (149-224 days) may have affected IHC 
staining and/or efficacy of antigen retrieval. This could alter results by affecting the 
precision of quantified pathology in the tissue. In addition, the free-floating IHC protocol 
generated small tears in the cortical gray mater. Any tears were excluded to reduce under 
sampling in the overall count during stereological analysis, and all visible objects that 
met positive counting criteria within the region of interest were used. 
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RESULTS 
Stereology Results  
 The NFT density was evaluated using the estimated total number of objects in the 
region of interest, divided by the planimetric volume sampled. The total number estimate 
(n) for the temporal poles assessed via the optical fractionator is found using the 
following formula: n = 1/ssf * 1/asf * 1/tsf * ΣQ, in which Q = counted objects, ssf = 
fraction of sections sampled, asf = dissector area divided by sampling grid area, and tsf = 
height of dissector divided by the average thickness of mounted tissue. The average tissue 
height was 24.46µm (38.9% shrinkage). The coefficient of error (CE-Gunderson; M=1) 
associated with each NFT population estimate was between 0.03-0.05 for all cases (Table 
6). Based on the stereologically quantified NFT density, the specimens were grouped in 
the following groups based on relative severity: High (VA3), Medium (VA1, VA2), and 
Low (VA4, VA5) (Table 7). 
 The total plaque load is reported as a percentage of DAB-positive area in the user-
defined ROI (temporal pole cortex). The area fraction was estimated by dividing the 
number of points intersecting DAB-staining above background intensity (plaque area) by 
the total number of points (plaque and non-plaque cortical area), as described by the 
following formula: Y,ref = [Σmi=1 P(Y)i] / [Σmi=1 P(ref)i], in which P(ref) = points 
associated with reference volume, Y = sub-region area, P(Y) = points hitting sub-region. 
The area sampled was estimated using the following formula: A = (1/asf) * a(p) * P(Yi), 
in which asf = area sampling fraction, a(p) = the area associated with each point, and 
P(Yi) = the number of countable points. Based on the stereologically quantified plaque 
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load, the specimens were grouped based on relative severity: High (VA3), Medium (VA1, 
VA2), and Low (VA4, VA5) (Table 8). The specific specimens in each group were 
consistent across both NFT and amyloid plaque analyses. 
Correlating NIR Scatter with AD Pathology  
 These preliminary stereological results suggest that a severity of NFT and 
amyloid plaques in the temporal pole can be correlated with in vitro scattering 
coefficients derived by NIR spectroscopy. Future studies using these values will compare 
the relative quantities of AD pathology with NIR scattering data using a non-parametric 
correlation coefficient (Kendall-tau analysis). The extent of correlation will potentially 
serve as an additional criterion for diagnosing dementia, as it would facilitate early 
detection and quantification of AD pathology, which is currently only assessed during 
autopsy. The ability to not only detect, but estimate quantity of these lesions non-
invasively with NIRS is especially important, as the total quantity of NFTs has been 
shown to correlate with severity of cognitive decline throughout Alzheimer’s disease, and 
severity of both lesions are traditionally diagnostically useful criteria in post-mortem 
analysis (Takayama, et al., 2016; Braak & Braak, 1991; Braak, et al., 2006). 
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DISCUSSION 
 
Spectroscopic Detection of AD Pathology 
 The described application of NIRS has previously been shown to detect AD 
pathology via scattering coefficients associated with the presence of NFTs and NPs 
(Hanlon, et al., 1999; Hanlon, et al., 2008). The current study is a first step in supporting 
the assumptions of this prior research, including the observations that a near-infrared 
signal at the wavelengths described penetrates cerebral tissue to a depth required to 
interface with AD pathology, as well as the assertion that the observed spectra are 
affected by molecular features of the tissue. Furthermore, this future studies will validate 
that transmission/reflection spectra of near-infrared light can be used to extrapolate 
evidence of the severity or quantities of NPs and NFTs in AD. As shown in Hanlon, et al. 
(2008), it was observed NPs and NFTs in cerebral tissue contribute changes in the overall 
scattering coefficient that correspond with their relative severities. 
 Overall, these findings further demonstrate that optical spectroscopy can be used 
to obtain information concerning the cellular environment of diseased tissue, which is 
required for future use of NIRS as a diagnostic tool. 
Technical Advantages of NIRS as a Neuroimaging Tool 
 NIRS has several technical advantages over other widely used neuroimaging 
methodologies such as (f)MRI, PET, and CSF screening. Studies involving NIRS do not 
require cumbersome equipment, are non-invasive/inexpensive, acquire data quickly, are 
forgiving to subject movement, and do not require the use of exogenous compounds to 
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yield meaningful data. In a clinical context, this ease-of-use may improve treatment for 
physically-limited or severely demented patients. Furthermore, anxiety and phobias may 
prevent the logistical and ethical use of PET or MRI scanners in patients with associated 
psychiatric conditions. 
In vivo Considerations of NIRS 
 The described implementation of NIRS can have potential diagnostic value in AD 
if adapted for clinical use in living subjects. The spectroscopic examination of cerebral 
pathology in vivo requires signal penetration to a depth within the cortex, as well as 
consideration of potential optical events in the overlying CSF, skin and bone. Previous 
studies have examined the NIR optical path shape/depth in order to correct for the 
contribution of these tissue layers to the near-infrared signal. These studies describe 
optical considerations for scatter, shape/depth and sensitivity as the signal propagates into 
the cortex (Okada, et al., 1997; Okada, et al., 1995; Zhang, et al., 2005). These reports 
suggest that a NIR signal can be used non-invasively to penetrate to the depth of AD 
pathology, and satisfactory study design can eliminate the influence of unrelated optical 
events. Furthermore, the distance between the NIR delivery and collection optics can be 
increased to subsequently increase the depth of penetration. This is an important 
consideration for in vivo use of NIRS for AD diagnosis, as it allows for the acquisition of 
additional spectra encompassing the entire depth of cortical AD pathology.  
 In vivo application of NIRS to detect AD pathology would ideally convey 
information with diagnostic significance. To accomplish this, future in vivo study design 
must be informed by knowledge of the neuropathology and clinical course of AD. 
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Recently, a prototype for in vivo NIRS has been developed that meets these concerns by 
targeting the temporal cortex, a region of the brain characterized by early amyloid and 
NFT deposition (Hanlon & Greco, 2015). The temporal cortex is covered by thin tissue 
and bone that allows for optimal detection of pathology in the underlying tissue using 
NIRS. As shown in Figure 10, measurements are made in vivo via delivery and detection 
probes that propagate a NIR signal to a software interface (Hanlon & Greco, 2015). As 
described previously, the distance between source and detection probes can be increased 
systematically to alter the photon path and maximize the amount of temporal cortex 
contributing to the scattered signal. The NIR spectra observed by the detection probe are 
analyzed using custom software to generate a diagnostically relevant scattering 
coefficient that corresponds with underlying tissue pathology. 
Clinical Applications of NIRS 
 The use of NIRS to diagnose AD would be ideal if applied by primary care 
physicians in a clinical setting. Currently, AD is generally diagnosed at age 65 or older, at 
which time irreversible pathophysiological changes have already occurred (Jack Jr, et al., 
2009). AD-associated Aβ plaques and NFTs have been observed decades prior to clinical 
assessment, and in individuals with MCI who may later develop AD (Vlassenko, et al., 
2012; Thal, et al., 2002). Therefore, the implementation of a sufficiently sensitive NIRS 
system could presumably detect AD at the earlier stages of the disease, at which point 
therapeutic intervention could be administered to salvage cognitive function later in life.  
 NIRS has the potential to improve patient outcomes as part of the normal geriatric 
clinical regimen. Screening for neurological abnormalities could be easily performed at 
	40 
point-of-care. One consideration for this type of spectroscopic analysis in a non-
laboratory setting is the influence of ambient light on optical measurements, which could 
be minimized by administering the test in a completely dark room or using an opaque 
barrier. The administrator of the test would require only procedural knowledge of data 
collection and access to a calibrated NIRS-device, which are small and rudimentary 
compared to other neuroimaging devices (MRI/PET/CT). In fact, portable NIRS-devices 
already exist, and have been successfully used for comparable screening and early 
identification of traumatic brain injury (TBI) on a large scale (Long, et al., 2017). 
Clinically-acquired spectroscopic data could be easily incorporated into a patient’s 
medical history in the form of an individualized “NIRS Patient Profile.” This profile 
could be used to evaluate potential risk by: A) comparing patient data to age-matched 
representative scattering profiles, or B) tracking neurological changes in an individual 
throughout aging.  
 Future applications of more sensitive NIR systems may also help clinicians 
differentiate between similar neurological conditions. As symptoms manifest in the 
progression of psychiatric diseases such as AD, Lewy Body disease and Parkinsonism, 
NIRS has the potential to detect the presence of disease-specific pathology based on 
characteristics of the near-infrared spectra associated with each disorder. This could be 
especially impactful in discerning specific variants of neurocognitive disorders that 
present clinically with similar symptoms. Furthermore, autopsies of demented elderly 
individuals in community dwellings often shows mixed brain pathology (Schneider, et 
al., 2007). In this capacity, NIRS may be used in conjunction with cognitive tests to 
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improve diagnostic precision in cases of generalized dementia for which the specific 
biochemical pathology is mixed or otherwise not known. While the experimental value of 
NIRS is promising, the specific applications of in vivo NIRS must be evaluated further 
before use in clinical settings. 
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CONCLUSIONS 
 
 The application of NIR scattering described in this thesis can have diagnostic 
value in AD if adapted for in vivo detection of cerebral pathology in living subjects. The 
value of this system lies in its ability to simply detect cellular and biochemical changes 
quickly, cheaply, non-invasively, and without side effects. As knowledge of the specific 
pathology underlying early AD and MCI improves, NIRS can likely be used to recognize 
features associated with these conditions. Further application of this system for diagnoses 
of related psychiatric disease must be evaluated in the specific contexts of each disease’s 
cerebral pathology and its subsequent effect on the NIR spectra. 
 NIRS has already been shown to be a diverse and valuable technique in ex vivo 
and in vivo studies of cerebral pathology. This study is an additional step towards 
widespread use of NIRS in clinical contexts. Future studies investigating the use of this 
system in the context of neuropsychiatric diseases have the potential to improve clinical 
outcomes for AD patients by providing an earlier diagnosis, tracking changes in 
pathology, and evaluating the effectiveness of current and future pharmaceutical 
interventions.
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Figure 1: MCI Clinical Outcomes 
 
Fig. 1 MCI patients can have multiple cognitive outcomes, including stable MCI, or further cognitive 
decline resulting from AD or non-AD dementia. Adapted from (McKhann, et al., 2011). 
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Figure 2: Amyloid Plaque IHC
 
Fig.2  The black arrows indicate 6E10-positive dense core plaques located in the temporal pole cortex. 
Dense core plaques are a hallmark histopathological feature of AD, and are typically surrounded by 
dystrophic neurites and activated microglia (not shown). Image captured using Stereo Investigator (MBF 
Biosciences) at 200x magnification. 
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Figure 3: Neuritic Plaque IHC 
 
Fig. 3 The stars indicate two AT8-positive immunostained neuritic plaques (NPs) containing tau-positive 
dystrophic neurites in the temporal pole cortex. The red arrow indicates a AT8-positive neurofibrillary 
tangle in the bottom left region of the figure. Image captured using Stereo Investigator (MBF Biosciences) 
at 100x magnification. 
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Figure 4: Amyloidogenic processing of APP 
 
Fig. 4 The production of beta-amyloid (Aβ) occurs via the amyloidogenic proteolytic pathway. 
Membrane-bound enzymes β- and y-secretase cleaves the N- and C- terminal domains of APP to produce 
insoluble Aβ peptide. Once in the extracellular space, Aβ forms aggregates into fibrils that compose 
amyloid plaques. Figure prepared in Microsoft PowerPoint 2015. Adapted from O’Brien & Wong, 2011). 
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Figure 5: Neurofibrillary Tangle (NFT) IHC 
 
Fig. 5 The figure shows two immunostained NFTs in a field of PHF-positive dystrophic neurite 
processes. Image captured using Stereo Investigator (MBF Biosciences) at 200x magnification. 
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Figure 6: Coronal Sections through Temporal Pole (A-F)  
 
 
 
Fig. 6 Schematic showing representative coronal sections through the right-hemisphere temporal pole. 
A-F moves along the Z-axis (anterior to posterior) through the temporal pole. Figure prepared using Adobe 
Illustrator CS6. 
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Figure 7: Area Fraction Fractionator for Amyloid Quantification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
A 
B B) Schematic showing Area 
Fraction Fractionator probe with 
Amyloid markers (red circles) 
deployed. The unlabeled areas will 
be marked with Non-amyloid 
markers to represent cortical tissue. 
To determine the area fraction 
(plaque load), the number of 
staining markers is divided by the 
total number of markers analyzed. 
 
A) Schematic showing specific 
location of Area Fraction 
Fractionator deployed by 
StereoInvestigator software. 
Each cross represents a point 
that is subsequently marked by 
an Amyloid or Non-amyloid 
marker. 
 
	50 
Figure 8: Temporal Cortex ROI Delineation  
 
Fig. 8 The region of interest (ROI) for stereological quantification was the whole cortex of the temporal 
pole. Representative slides were stained with thionin to delineate Gray/White matter boundaries. The red 
hashed line (top) represents the top boundary of the established ROI. The black hashed- line (bottom) 
represents the bottom boundary of the ROI. Image captured using MBF Biosciences Stereo investigator 
(10x magnification). 
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Figure 9: Optical Fractionator for NFT Quantification  
 
 
A)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A 
B B) Schematic showing 
specific location of 
Optical Fractionator 
probe. Green lines 
indicate inclusion of 
countable objects. Red 
lines indicate exclusion 
of countable objects. In 
the above figure, 3 
countable NFT are 
represented, and marked 
by white arrows. Figure 
prepared using MBF 
Biosciences Stereo 
Investigator and Apple 
Preview. 
 
A) Systemic random 
sampling field chosen 
by StereoInvestigator 
software. 
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Figure 10: In vivo NIRS System
 
Fig. 10 In the proposed NIRS system, the signal is delivered to the subject’s head above the temporal 
cortex. The optical signal is detected via a group of collection fibers that feed into a spectrometer. The 
signal is modified via charge coupled device (CCD) and the NIR spectra of a defined wavelength interval is 
analyzed via computer software. Figure prepared using Adobe Illustrator CS6. Adapted from (Hanlon & 
Greco, 2015). 
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Table 1. Classification of Cognitive Impairment in AD 
 Learning Deficiency Language Deficiency  Perception 
Deficiency 
Amnestic Anterograde Amnesia n/a n/a 
Nonamnestic n/a Object Agnosia Anomic Aphasia 
Spatial Impairment 
Prosopagnosia 
Executive 
Dysfunction Impaired Problem Solving n/a Impaired Judgement 
 
  
	54 
 
Table 2. Biochemistry of Related Neuropathological Conditions 
 Alzheimer’s Dementia 
Huntington 
Disease 
Parkinson’s 
dementia 
Lewy Body 
Dementia 
Frontotempor
al dementia 
Demographic 65+ years old 40+ years old  60+ years old 
75 years old 
(average) 
50-70 years old 
 
Early Affected 
brain regions Temporal cortex 
Caudate 
nuclei 
Substantia nigra 
(zonal compacta) 
Neocortex 
Brainstem 
Frontal lobe 
Temporal lobe 
Pathological 
Proteins 
Beta-amyloid 
PHF-tau Huntingtin Alpha-synuclein 
Beta-amyloid 
PHF-tau 
Alpha-
synuclein 
PHF-tau 
Alpha-
synuclein 
Associated 
Cellular 
Pathology 
NFTs 
NPs 
Atrophy 
Atrophy Lewy Bodies Lewy Neurites 
NFTs 
NPs 
Atrophy 
Lewy Bodies 
 
Frontotemporal 
lobar 
degeneration 
(FTLD) 
NFTs 
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Table 3. Characterization of IHC antibodies 
Clone Antigen Immunogen Conc. Isotype Reactivity Clonality 
Distributo
r Catalog  
AT8 
Ser202, 
Thr205 
(PHF-Tau) 
Partially 
purified 
human 
PHF-Tau 
0.1 mg/mL Mouse IgG1 Human 
Monoclona
l 
Thermo 
Fisher 
#MN1020
B 
6E10 
Amino 
acid 
residue 1-
16 (beta 
amyloid) 
N/A 1.0 mg/mL Mouse IgG1 Human 
Monoclona
l Biolegend #803002 
 
	56 
Table 4: Stereological Parameters for Area Fraction Fractionator  
 
  
ROI 
Section Interval 
(ssf) 
Sampling 
Grid Area 
(µm2) 
Counting 
Frame  (µm) 
Area sampling 
fraction (µm) 
Grid Spacing 
(µm) 
Avg. Sites 
Sampled 
Cortex 1/16 3750000 (2500 x 1500) 
422500 
(650 x 650) 0.1127 65 963 
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Table 5: Stereological Parameters for Optical Fractionator 
ROI Section Interval (ssf) 
Sampling Grid 
Area (µm2) 
Counting frame 
area (µm2) 
Dissector height 
(µm) 
Guard Zone 
(µm) 
Cortex 1/32 4662757 (3175.4 x 1468.4) 
74529 
(273 x 273) 20.0 1.0 
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Table 6: Stereology results for NFT quantification 
Sample Number of Sampling Sites 
Defined 
Thickness 
(µm) 
Estimated NFT Population using Mean 
Section Thickness with Counts 
CE-Gunderson 
M=1 
VA1 390 24.3 3835780 0.03 
VA2 368 23.9 3417945 0.03 
VA3 364 24.8 5743433 0.03 
VA4 388 24.2 1679177 0.04 
VA5 373 25.1 1077397 0.05 
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Table 7. NFT Density 
Sample NFT Density (tangles/mm3) SEM Sections counted 
VA1 2359.2 ±218.8 6 
VA2 2155.6 ±106.6 7 
VA3 3430.0 ±153.9 9 
VA4 994.3 ±41.65 6 
VA5 633.2 ±72.6 6 
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Table 8. Amyloid Plaque Load 
Sample Plaque Load SEM Sections counted 
VA1 0.1279 ±0.003689 12 
VA2 0.1228 ±0.003080 16 
VA3 0.16048 ±0.004867 13 
VA4 0.08637 ±0.003752 10 
VA5 0.09420 ±0.001656 12 
 
 
 
 
  
Amyloid Plaque Load 
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APPENDIX A 
 
50mM TBS 2000mL 12.1 Tris Base (g) 
  18 NaCl (g) 
  2000 ddH2O (mL) 
3% H2O2  10mL 1 H2O2 (mL) 
  9 0.05M TBS (mL) 
10mM Na-Citrate Buffer 1000ml 2.94 Tri-sodium citrate dihydrous (g) 
  950 ddH2O (mL) 
  500 Triton X-100 (µL) 
DAB Solution  50 0.05M TBS (mL) 
 50mL 10 DAB (mg) 
  4.15 30% H2O2 (µL) 
0.05% Thionin Stain 1000mL  37 Sodium Acetate anhydrous (g) 
  500 Thionin Acetate (mg) 
  
	62 
REFERENCES 
Aho, L. et al., 2010. Immunohistochemical Visualization of Amyloid-B Protein Precursor 
and Amyloid-B in Extra- and Intracellular Compartments in the Human Brain. Journal of 
Alzheimer's Disease, Volume 20, pp. 1015-28. 
Albert, M. et al., 2011. The diagnosis of mild cognitive impairment due to Alzheimer's 
disease: recommendations from the National Institute on Aging-Alzheimer's Association 
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers & Dementia, 
7(3), pp. 270-9. 
Alfano, R., Tata, D. & Coredero, J., 1984. Laser induced fluorescence spectroscopy from 
native cancerous and normal tissue. IEEE Journal of Quantum Electronics, Volume 
QE20, pp. 1507-11. 
Alzheimer, A., 1987. About a peculiar disease of the cerebral cortex. Alzheimer Disease 
& Associated Disorders, Volume 1, pp. 3-8. 
American Psychiatric Association, 2013. Diagnostic and Statisical Manual of Mental 
Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Association 
Publishing. 
Armstrong, R., 2014. A critical analysis of the 'amyloid cascade hypothesis'. Folia 
Neuropathologica, 52(3), pp. 211-25. 
Arnold, S. et al., 1991. The topographical and neuroanatomical distribution of 
neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with 
Alzheimer’s disease. Cerebral Cortex, Volume 1, pp. 103-16. 
Baumgart, M. et al., 2015. Summary of the evidence on modifiable risk factors for 
cognitive decline and dementia: A population-based perspective. Alzheimer's & 
Dementia, 11(6), pp. 718-26. 
Braak, H. et al., 2006. Staging of Alzheimer disease-associated neurofibrillary pathology 
using paraffin sections and immunhistochemistry. Acta Neuropathologica, Volume 112, 
pp. 389-404. 
Braak, H. & Braak, E., 1991. Neuropathological stageing of Alzheimer-related changes. 
Acta Neuropathologica, 82(4), pp. 239-259. 
Braak, H. & Del Tredici, K., 2011. The pathological process underlying Alzheimer's 
disease in individuals under thirty. Acta Neuropathologica, 121(2), pp. 171-81. 
	63 
Brookmeyer, R., Johnson, E., Ziegler-Graham, K. & Arrighi, H., 2007. Forecasting the 
global burden of Alzheimer's disease. Alzheimer's & dementia: the journal of the 
Alzheimer's Association, 3(3), pp. 186-191. 
Cardenas, V. et al., 2011. Brain atrophy associated with baseline and longitudinal 
measures of cognition. Neurobiology & Aging, 32(4), pp. 572-80. 
Choo, L. et al., 1995. Infrared spectra of human central nervous system tissue: diagnosis 
of Alzheimer's disease by multivariate analyses. Biospectroscopy, Volume 1, pp. 141-8. 
Cleveland, D., Hwo, S. & Kirschner, M., 1977. Purification of tau, a microtobule-
associated protein that induces assembly of microtubules from purified tubulin. Journal 
of Molecular Biology, 116(2), pp. 207-25. 
Cohen, S., Linse, A., Luheshi, S. & Leila, M., 2013. Proliferation of amyloid-beta 42 
aggregates occurs through a secondary nucleation mechanism. Proceedings of the 
National Academy of Sciences of the United States of America, 110(24), pp. 9758-53. 
Cui, X. et al., 2011. A quantitative comparison of NIRS and fMRI across multiple 
cognitive tasks. Neuroimage, 54(4), pp. 2808-21. 
Dani, M., Brooks, D. & Edison, P., 2016. Tau imaging in neurodegenerative diseases. 
European Journal of Nuclear Medicine and Molecular Imaging, 43(6), pp. 1139-50. 
Dawkins, E. & Small, D., 2014. Insights into the physiological function of the β-amyloid 
precursor protein: beyond Alzheimer's disease. Journal of Neurochemistry, 129(5), pp. 
756-69. 
DeKosky ST, S. S., 1990. Synapse loss in frontal cortex biopsies in Alzheimer's disease: 
correlation with cognitive severity. Annals of Neurology, 27(5), pp. 457-62. 
De-Paula, V., Radanovic, M., Diniz, B. & Forlenza, O., 2012. Alzheimer's Disease. In: J. 
Harris, ed. Subcellular Biochemistry. s.l.:Springer Press, pp. 392-352. 
Dickerson, B. et al., 2009. The cortical signature of Alzheimer’s disease: Regionally 
specific cortical thinning relates to symptom severity in very mild to mild AD dementia 
and is detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex, 
Volume 19, pp. 497-510. 
Dickerson, B. et al., 2011. Alzheimer-signature MRI biomarker predicts AD dementia in 
cognitively normal adults. Neurology, Volume 76, pp. 1395-1402. 
Dickson, D., 2010. Neuropathology of Non-Alzheimer Degenerative Disorders. 
International Journal of Clinical & Experimental Pathology, 3(1), pp. 1-23. 
	64 
Farias, S. et al., 2009. Progression of mild cognitive impairment to dementia in clinic-vs 
community-based cohorts. Archives of Neurology, 66(9), pp. 1151-7. 
Ferreri, L., Bigand, E., Perrey, S. & Bugaiska, A., 2014. The promise of Near-Infrared 
Spectroscopy (NIRS) for psychological research: A brief review. L’Année psychologique, 
Volume 114, pp. 537-569. 
Forsberg, A. et al., 2008. PET imaging of amyloid deposition in patients with mild 
cognitive impairment. Neurobiology of Aging, 29(10), pp. 1456-65. 
Fratiglioni, L., Strauss, E. & Qiu, C., 2008. Epidemiology of the dementias of old age. In: 
T. Dening, R. Jacoby, C. Oppenheimer & A. Thomas, eds. The Oxford Textbook of Old 
Age Psychiatry. 4th ed ed. New York(NY): Oxford University Press, pp. 391-406. 
Glenner, G. & Wong, C., 1984. Alzheimer's disease and Down's syndrome: sharing of a 
unique cerebrovascular amyloid fibril protein. Biochemical and Biophysical Research 
Communications, Volume 122, pp. 1131-5. 
Goedert, M., Jakes, R. & Vanmechelen, E., 1995. Monoclonal antibody AT8 recognises 
tau protein phosphorylated at both serine 202 and threonine 205. Neuroscience Letters, 
189(3), pp. 167-9. 
Goedert, M., Spillantini, M., Cairns, N. & Crowther, R., 1992. Tau proteins of Alzheimer 
paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron, 
8(1), pp. 159-68. 
Goedert, M., Spillantini, M. & Davies, S., 1998. Filamentous nerve cell inclusions in 
neurodegenerative diseases. Current Opinion in Neurobiology, Volume 8, pp. 619-32. 
Haas, C, Kaether, C., Thinakaran, G. & Sisodia, S., 2012. Trafficking and Proteolytic 
Processing of APP. Cold Spring Harbor Perspectives in Medicine, 2(5). 
Hanlon, E. & Greco, F., 2015. Spectroscopic detection of brain damage. USA, Patent No. 
US 8954133 B1. 
Hanlon, E. et al., 1999. Near-infrared Fluorescence Spectroscopy Detects Alzheimer's 
Disease In Vitro. Photochemistry and Photobiology, 70(2), pp. 236-242. 
Hanlon, E. et al., 2008. Scattering differentiates Alzheimer disease in vitro. Optics 
Letters, 33(6), pp. 624-6. 
Hardy, J. & Higgins, G., 1992. Alzheimer's Disease: The amyloid cascade hypothesis. 
Science, Volume 256, pp. 184-5. 
Hardy, J. & Selkoe, D., 2002. The amyloid hypothesis of Alzheimer's disease: progress 
and problems on the road to therapeutics. Science, Volume 297, pp. 353-6. 
	65 
Hebert, L., Weuve, J., Scherr, P. & Evans, D., 2013. Alzheimer disease in the United 
States (2010-2050) estimated using the 2010 Census. Neurology, 80(19), pp. 1778-83. 
Hintersteiner, M., Enz, A., Frey, P. & al., e., 2005. In vivo detection of amyloid-beta 
deposits by near-infrared imaging using an oxazine-derivative probe. Nature 
Biotechnology, 23(5), pp. 577-83. 
Horvath, K., Schomacker, K., Lee, C. & Cohn, L., 1994. Intraoperative myocardial 
ischemia detection with laser-induced fluorescence. Journal of Thoracic Cardiovascular 
Surgery, Volume 107, pp. 220-5. 
Huang, W. et al., 2004. APOE genotype, family history of dementia, and Alzheimer 
disease risk: a 6-year follow-up study. Archives of Neurology, Volume 61, pp. 1930-4. 
Hyman, B., Marzloff, K. & Arriagada, P., 1993. The lack of accumulation of senile 
plaques or amyloid burden in Alzheimer’s disease suggests a dynamic balance between 
amyloid deposition and resolution. Journal of Neurolopathology & Experiment 
Neurology, Volume 52, pp. 594-600. 
Ingelsson, M. et al., 2004. Early Abeta accumulation and progressive synaptic loss, 
gliosis, and tangle formation in AD brain. Neurology, 62(6), pp. 925-31. 
Itagaki, S. et al., 1989. Relationship of microglia and astrocytes to amyloid deposits of 
Alzheimer disease. Journal of Neuroimmunology, 23(3), pp. 173-82. 
Jack Jr, C. et al., 2008. 11C PiB and structural MRI provide complementary information 
in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain, 
Volume 131, pp. 665-80. 
Jack Jr, C. et al., 2009. Serial PIB and MRI in normal, mild cognitive impairment and 
Alzheimer's disease: implications for sequence of pathological events in Alzheimer's 
disease. Brain, 132(5), pp. 1355-65. 
Jellinger, K., 1990. Morphology of Alzheimer's disease and related disorders. In: K. 
Maurer, P. Riederer & H. Beckmann, eds. Alzheimer's Disease. Epidemiology, 
Neuropathology, Neurochemistry, and Clinics. s.l. Springer Vienna, pp. 61-77. 
Jobis, F., 1977. Non-invasive, infrared monitoring of cerebral and myocardial oxygen 
sufficiency and circulatory parameters. Science, Volume 198, pp. 1264-7. 
Jobsis-Vandervliet, F., 1999. Discovery of the near-infrared window into the body and 
the early development of near-infrared spectroscopy. Journal of Biomedical Optics, 4(4), 
pp. 392-6. 
	66 
Johnson, K., Fox, N., Sperling, R. & Klunk, W., 2012. Brain Imaging in Alzheimer 
Disease. Cold Spring Harbor Perspectives in Medicine, 2(4), p. a006213. 
Karran, E., Mercken, M. & De Strooper, B., 2011. The amyloid cascade hypothesis for 
Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews 
Drug Discovery, Volume 10, pp. 698-712. 
Khachaturian, K., 1985. Diagnosis of Alzheimer's Disease. Archives of Neurology, 
42(11), pp. 1097-105. 
Klunk, W., Engler, H. & Nordberg, A., 2004. Imaging brain amyloid in Alzheimer's 
disease with pittsburgh compound-B. Annals of Neurology, 55(3), pp. 309-19. 
Lacor, P. et al., 2007. Abeta oligomer-induced aberrations in synapse composition, shape, 
and density provide a molecular basis for loss of connectivity in Alzheimer's Disease. 
Journal of Neuroscience, 27(4), pp. 796-807. 
Lam, S; Macaulay, C; Palcic, B, 1993. Detection and localization of early lung cancer by 
imaging techniques. Chest, Volume 103, pp. 12s-14s. 
Lambert, J. et al., 2013. Meta-analysis of 74,046 individuals identifies 11 new 
susceptibility loci for Alzheimer's disease. Nature Genetics, 45(12), pp. 1452-U206. 
Laske, C. et al., 2011. Identification of a blood-based biomarker panel for classification 
of Alzheimer's disease. International Journal of Neuropsychopharmacology, 14(9), pp. 
1147-55. 
Lee, V., Balin, B., Otvos, L. & Trojanowski, J., 1991. A68: a major subunit of paired 
helical filaments and derivative forms of normal Tau. Science, 251(4994), pp. 675-8. 
Lista, S. et al., 2014. CSF Aβ1-42 combined with neuroimaging biomarkers in the early 
detection, diagnosis and prediction of Alzheimer's disease. Alzheimer's & Dementia, 
10(3), pp. 381-92. 
Logothetis, N. et al., 2011. Neurophysiological investigation of the basis of the fMRI 
signal. Nature, 412(6843), pp. 150-7. 
Long, X. et al., 2017. Portable near-infrared rapid detection of intracranial hemorrhage in 
Chinese population. Journal of Clinical Neuroscience, pp. E-publication ahead of press. 
Lue, L. et al., 1999. Soluble amyloid beta peptide concentration as a predictor of synaptic 
change in Alzheimer's disease. The American Journal of Pathology, 155(3), pp. 853-62. 
Mandelkow , E., 1988. Tau in Alzheimer's disease. Trends in Cell Biology, 8(11), pp. 
425-7. 
	67 
Mandelkow, E. et al., 1993. Microtubule-associated Protein Tau, Paired Helical 
Filaments, and Phosphorylation. Annals of the New York Academy of Sciences, Volume 
695, pp. 209-16. 
McKhann, G. et al., 2011. The diagnosis of dementia due to Alzheimer's disease: 
Recommendations from the National Institute on Aging and the Alzheimer's Association 
Workgroup. Alzheimer's & Dementia, pp. 1-7. 
Mirra, S., Gearing, M. & Nash, F., 1997. Neuropathological assessment of Alzheimer's 
disease. Neurology, Volume 49, pp. S14-S16. 
Mirra, S. et al., 1991. The Consortium To Establish A Registry For Alzheimer's-Disease 
(CERAD). 2. Standardization of The Neuropathologic Assessment of Alzheimer's 
Disease. Neurology, 41(4), pp. 479-486. 
Mosconi, L., 2005. Brain glucose metabolism in the early and specific diagnosis of 
Alzheimer's disease. FDG-PET studies in MCI and AD. European Journal of Nuclear 
Medicine and Molecular Imaging, 32(4), pp. 486-510. 
Mosconi, L. et al., 2008. Hypometabolism and altered cerebrospinal fluid markers in 
normal apoplipoprotein E (E4) carriers with subjective memory complaints. Biology of 
Psychiatry, 63(6), pp. 609-18. 
Nho, K. et al., 2012. Voxel and surface-based topography of memory and executive 
deficits in mild cognitive impairment and Alzheimer's disease. Radiology & Imaging 
Sciences, 6(4), pp. 441-67. 
O'Brien, R. & Wong, R., 2011. Amyloid precursor protein processing and Alzheimer's 
disease. Annual Reviews: Neuroscience, Volume 34, pp. 185-204. 
Okada, E., Firbank, M. & Delpy, D., 1995. The effect of overlying tissue on the spatial 
sensitivity profile of near-infrared spectroscopy. Physics in Medicine & Biology, 40(12), 
pp. 2093-108. 
Okada, E. et al., 1997. Theoretical and experimental investigation of near-infrared light 
propagation in a model of the adult head. Applied Optics, 36(1), pp. 21-31. 
Palmqvist, S., 2016. Cerebrospinal fluid analysis detects cerebral amyloid-β 
accumulation earlier than positron emission tomography. Brain, 139(4), pp. 1226-36. 
Pei, J., Sjoegren, M. & Winblad, B., 2008. Neurofibrillary degeneration in Alzheimer's 
disease: from molecular mechanisms to identification of drug targets. Current Opinion in 
Psychiatry, 21(6), pp. 555-561. 
	68 
Perelman, L. et al., 1998. Observation of Periodic Fine Structure in Reflectance from 
Biological Tissue: A New Technique for Measuring Nuclear Size Distribution. Physical 
Review Letters, Volume 80, p. 627. 
Perez, M. et al., 2008. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) 
transgenic mice and Alzheimer disease. Acta Neuropathologica, 116(4), pp. 409-18. 
Perl, D., 2010. Neuropathology of Alzheimer's Disease. Mount Sinai Journal of 
Medicine, 77(1), pp. 32-42. 
Petersen, R., Smith, G. & Waring, S., 1999. Mild cognitive impairment: clinical 
characterization and outcome. Archives of Neurology, Volume 56, pp. 303-8. 
Pizzi, N. et al., 1995. Neural network classification of infrared spectra of control and 
Alzheimer's diseased tissue. Artificial Intelligence in Medicine, Volume 7, pp. 67-79. 
Prince, M., Albanese, E., Guerchet, M. & Prina, M., 2014. World Alzheimer Report 2014: 
Dementia and risk reduction: An analysis of protective and modifiable risk factors, 
London: Alzheimer's Disease International. 
Prince, M., Bryce, R. & Ferri, C., 2011. World Alzheimer Report 2011: The benefits of 
early diagnosis and intervention, London: Alzheimer's Disease International. 
Qiu, C., Kivipelto, M. & Strauss, E., 2009. Epidemiology of Alzheimer's disease: 
occurrence, determinants, and strategies toward intervention. Dialogues in Clinical 
Neuroscience, 11(2), pp. 111-128. 
Reitz, C., 2012. Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical 
Review. International Journal of Alzheimer's Disease. 
Ringman, J. et al., 2014. Clinical predictors of severe cerebral amyloid angiopathy and 
influence of APOE genotype in persons with pathologically verified Alzheimer disease. 
JAMA Neurology, 71(7), pp. 878-83. 
Risacher, S. & Saykin, A., 2013. Neuroimaging Biomarkers of Neurodegenerative 
Diseases and Dementia. Seminars in Neurology, 33(4), pp. 386-416. 
Ryan, N. & Rossor, M., 2010. Correlating familial Alzheimer's disease gene mutations 
with clinical phenotype. Biomarkers in Medicine, 4(1), pp. 99-112. 
Scahill, R. et al., 2002. Mapping the evolution of regional atrophy in Alzheimer's disease: 
unbiased analysis of fluid-registered serial MRI. Proceedings of the National Academy of 
Sciences USA, 99(7), pp. 4703-7. 
	69 
Schmand, B., Huizenga, H. & van Gool, W., 2010. Meta-analysis of CSF and MRI 
biomarkers for detecting preclinical Alzheimer's disease. Psychological Medicine, 40(1), 
pp. 135-45. 
Schneider, J., Arvanitakis, Z., Bang, W. & Bennett, D., 2007. Mixed brain pathologies 
account for most dementia cases in community-dwelling older persons. Neurology, 
69(24), pp. 2197-204. 
Schneider, J., Arvanitakis, Z., Leurgans, S. & Bennett, D., 2009. The Neuropathology of 
Probable Alzheimer's Disease and Mild Cognitive Impairment. Annals of Neurology, 
66(2), pp. 200-208. 
Selkoe, D., 2001. Alzheimer's disease: genes, proteins, and therapy. Physiological 
Reviews, 81(2), pp. 741-86. 
Serrano-Pozo, A., Frosch, M., Masliah, E. & Hyman, B., 2011. Neuropathological 
Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 1(1). 
Small, S. & Duff, K., 2008. Linking Abeta and tau in late-onset Alzheimer's disease: a 
dual-pathway hypothesis. Neuron, 60(4), pp. 534-42. 
Sperling, R. et al., 2011. Toward defining the preclinical stages of Alzheimer's disease: 
Recommendations from the National Institute on Aging-Alzheimer's Association 
workgroups on diagnostic guidelines for Alzheimer's Disease. Alzheimers & Dementia, 
7(3), pp. 280-92. 
Sperling, R., Karlawish, J. & Johnson, K., 2013. Preclinical Alzheimer disease-the 
challenges ahead. Nature Reviews Neurology, 9(1), pp. 54-8. 
Spies, P., Verbeek, M., van Groen, T. & Claassen, J., 2012. Reviewing reasons for the 
decreased CSF Abeta42 concentration in Alzheimer disease. Frontiers in Bioscience 
(Landmark Edition), 1(17), pp. 2024-34. 
Stargardt, A., Swaab, D. & Bossers, K., 2015. Storm before the quiet, neuronal 
hyperactivity and Aβ in the presymptomatic stages of Alzheimer's disease. Neurobiology 
& Aging, 36(1), pp. 1-11. 
Steinbrink, J., Villringer, A., Kempf, F. & Obrig, H., 2006. Illuminating the bold signal: 
Combined fMRI-fNIRS studies. Magnetic Resonance Imaging, 24(4), pp. 495-505. 
Takayama, M. et al., 2016. Quantification of immunohistochemical findings of 
neurofibrillary tangles and senile plaques for a diagnosis of dementia in forensic autopsy 
cases. Legal Medicine, Volume 22, pp. 82-89. 
	70 
Terry, R., 1986. Interrelations among the lesions of normal and abnormal aging of the 
brain. Progress in Brain Research, Volume 70, pp. 41-8. 
Thal, D., Ghebredehin, E., Haass, C. & Schultz, C., 2002. UV light induced 
autofluorescence of full-length abeta protein deposits in the human brain. Clinical 
Neuropathology, Volume 21, pp. 35-40. 
Thal, D., Rub, U., Orantes, M. & Braak, H., 2002. Phases of Aβ-deposition in the human 
brain and its relevance for the development of AD. Neurology, Volume 58, pp. 1791-800. 
Tong, H., Lou, K. & Wang, W., 2015. Near-infrared fluorescent probes for imaging of 
amyloid plaques in Alzheimer׳s disease. Acta Pharmaceutica Sinica B, 5(1), pp. 25-33. 
Vassar, R., Kovacs, D., Yan, R. & Wong, P., 2010. The β-Secretase Enzyme BACE in 
Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic 
Potential. Journal of Neuroscience, 29(41), pp. 12787-94. 
Villemagne, V. et al., 2013. Amyloid β deposition, neurodegeneration, and cognitive 
decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurology, 
12(4), pp. 357-67. 
Villemagne, V. & Chetelat, G., 2016. Neuroimaging biomarkers in Alzheimer's disease 
and other dementias. Ageing Research Reviews, Volume 30, pp. 4-16. 
Visser, P., Verhey, F. & Hofman, P., 2002. Medial Temporal Lobe Atrophy predicts 
Alzheimer's disease in patients with minor cognitive impairment. Journal of Neurology, 
Neurosurgery, and Psychiatry, Volume 72, pp. 491-497. 
Vlassenko, A., Benzinger, T. & Morris, J., 2012. PET Amyloid-Beta Imaging in 
Preclinical Alzheimer's Disease. (BBA) Molecular and Cellular Biology of Lipids, 
1822(3), pp. 370-9. 
Weiner, M. et al., 2015. 2014 Update of the Alzheimer's Disease Neuroimaging 
Initiative: A review of papers published since its inception. Alzheimer's &  Dementia, 
11(6), pp. e1-e120. 
Wimo, A., Jonsson, L. & Winblad, B., 2006. An estimate of the worldwide prevalence 
and direct costs of dementia in 2003. Dementia and Geriatric Cognitive  Disorders, 
21(3), pp. 175-181. 
Wisniewski, H., Narang, H. & Terry, R., 1976. Neurofibrillary tangles of paired helical 
filaments. Journal of the Neurological Sciences, 27(2), pp. 173-81. 
	71 
Zhang, X., Toronov, V. & Webb, A., 2005. Simultaneous integrated diffuse optical 
tomography and functional magnetic resonance imaging of the human brain. Optics 
Express, 13(14), pp. 5513-21. 
Zhao, Y. et al., 2016. In vivo detection of microstructural correlates of brain pathology in 
preclinical and early Alzheimer Disease with magnetic resonance imaging. Neuroimage, 
Volume 148, pp. 294-304. 
 
  
	72 
CURRICULUM VITAE 
